Luseogliflozin

Luseogliflozin is a SGLT2 inhibitor used in the treatment of Type 2 diabetes. It is marketed in Japan by Taisho Pharmaceutical.

Mechanism of Action

Luseogliflozin works by inhibiting SGLT2, a protein in the kidneys that reabsorbs glucose into the bloodstream. By blocking this protein, luseogliflozin causes excess glucose to be eliminated in the urine, thereby lowering blood glucose levels.

Indications

Luseogliflozin is indicated for the treatment of adults with Type 2 diabetes who are not adequately controlled on diet and exercise alone. It may be used as monotherapy or in combination with other antidiabetic medications.

Side Effects

Common side effects of luseogliflozin include urinary tract infections, increased urination, and genital fungal infections. Rare but serious side effects include ketoacidosis, kidney injury, and severe allergic reactions.

Contraindications

Luseogliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also contraindicated in patients with a history of hypersensitivity to luseogliflozin or any of its components.

Interactions

Luseogliflozin may interact with other medications, including diuretics, insulin, and other antidiabetic drugs. Patients should inform their healthcare provider of all medications they are currently taking.

See Also

• Sodium-glucose cotransporter 2 inhibitors
• Type 2 diabetes
• Antidiabetic medication

Luseogliflozin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia